Le porte-parole canadien
de la biotechnologie
Nos membres
| Location: |
Saint-Laurent, Quebec |
| Industry Sector: |
Pharma |
| Website: |
abbott.ca |
| Contact: |
Dirk van Eeden (dirk.vaneeden@abbott.com)
1 514 832 7000
|
| Ownership: |
Subsidiary - Nyse: ABT |
| Description: |
Abbott Canada is an affiliate of Abbott and the first international office to be established. Today Abbott Canada employs some 2,000 individuals across the country with more than 300 based out of their headquarters in the Montreal borough of Ville Saint-Laurent. |
| Location: |
Mississauaga, Ontario |
| Industry Sector: |
Biotechnology - Therapeutics |
| Website: |
www.abraxisbio.com |
| Contact: |
Ann Heidebrecht (aheidebrecht@abraxisbio.com)
1 905 3662600
|
| Ownership: |
Subsidiary - Nasdaq: ABII |
| Description: |
Abraxis BioScience's activities are focused on the development and commercialization of next generation cancer therapies. |
| Location: |
Saskatoon, Saskatchewan |
| Industry Sector: |
Biotechnology - Therapeutics |
| Contact: |
Sanj Singh (sanj@adetherapeutics.com)
1 306 2615189
|
| Description: |
AdeTherapeutics is a privately-held clinical-stage drug development company focused in the areas of inflammation, and acute care medicine. AdeTherapeutics business strategy is to build a robust portfolio of high value products by developing and/or in-licensing clinical-stage ready therapeutic candidates that address significant unmet medical needs and rapidly move them through critical development stages (i.e. Phase II trials). |
| Location: |
Bethesda, Maryland |
| Industry Sector: |
Professional Services and Consulting |
| Website: |
www.adjuvant.com |
| Contact: |
(amartin@adjuvant.com)
1 301 830-6998
|
| Description: |
Adjuvant is a strategic management consulting company. Their consultants have experience working in successful public and start-up firms in the life science, healthcare, and technology markets. They have a unique perspective of
today's markets and trends, which has enabled them to identify unmet needs, invigorate established products, create profitable alliances, and launch new ventures.
In today's volatile marketplace, experience matters. Success is measured by your ability to quickly identify, analyze and act upon market opportunities. |
| Location: |
Edmonton, Alberta |
| Industry Sector: |
Biotechnology - other |
| Website: |
www.afexa.com |
| Contact: |
Jane Tulloch (ir@afexa.com)
1 780 4320022
|
| Ownership: |
Public - TSX: FXA |
| Description: |
Afexa Life Sciences Inc. is a health sciences and technology company, that discovers and biologically standardizes natural products that deliver consistent, verifiable and provable health benefits. |
| Location: |
Toronto, Ontario |
| Industry Sector: |
Biotechnology - Therapeutics |
| Website: |
www.afnm.com |
| Contact: |
Owen Roberts (oroberts@afnm.com)
1 416 645 6613
|
| Description: |
Affinium Pharmaceuticals is a specialty pharmaceutical company focused on the discovery and development of novel anti-infective medicines. Affinium's FASII antibacterial programs constitute a new antibiotic franchise with the potential for multiple products targeting the FASII pathway. |
| Location: |
Guelph, Ontario |
| Industry Sector: |
Public / Non-Profit Organizations |
| Website: |
www.afmnet.ca |
| Contact: |
Tania Framst (tania.framst@afmnet.ca)
1 519 8226253
|
| Description: |
From food safety to new products, cutting-edge research is making headway with the Advanced Foods and Materials Network (AFMnet), one of Canada's newest Networks of Centers of Excellence. This nationwide initiative brings together researchers in biochemistry, engineering, health, law and society who are focused on innovative aspects of food and materials. |
| Location: |
Ottawa, Ontario |
| Industry Sector: |
Public / Non-Profit Organizations |
| Website: |
www.aic.ca |
| Contact: |
Myles Frosst (mfrosst@aic.ca)
1 613 232 9459
|
| Description: |
The Agricultural Institute of Canada exists to build scientific capacity for the sustainable and profitable optimization of societal benefits that can be derived from the agro-economy. The agro-economy consists of all knowledge chains (from basic and applied research to innovation, commercialization and technology transfer) and all value chains that rely upon or focus upon agricultural output as a major input to final products. |
| Location: |
Ottawa, Ontario |
| Industry Sector: |
Biotechnology - other |
| Website: |
www.agrisoma.com |
| Contact: |
Steven F. Fabijanski (sfabijanski@agrisoma.com)
1 613 834 5265
|
| Description: |
Agrisoma Biosciences Inc. is a private agricultural biotechnology company using its leading edge ETL technology to create new crop varieties engineered for high-value applications such as biofuel production. |
| Location: |
Saskatoon, Saskatchewan |
| Industry Sector: |
Public / Non-Profit Organizations |
| Website: |
www.agwest.sk.ca |
| Contact: |
Ian McPhadden (ian.mcphadden@agwest.sk.ca)
1 306 975 1939
|
| Description: |
Ag-West Bio is a membership-based organization at the forefront of Saskatchewan’s bio-economy. Company act as a catalyst for partnerships and industry growth through investments, aiding strategic alliances, providing regulatory advice and communications. Membership has grown to include over 100 corporations, associations and individuals representing natural health products and functional foods, bio-products and bio-processes and agricultural biotechnology sectors. |
| Location: |
Toronto, Ontario |
| Industry Sector: |
Biotechnology - Therapeutics |
| Website: |
www.aimtherapeutics.com |
| Contact: |
Richard T. Timmer (rtimmer@aimtherapeutics.com)
1 416 673 8199
|
| Description: |
AIM Therapeutics is engaged in the discovery and development of breakthrough medical therapies to improve the lives of people with immune and inflammatory disorders. The company is focused on developing novel treatments for asthma, COPD, bronchitis, spinal cord injury, restenosis, type 1 diabetes and other inflammatory conditions with significant unmet medical needs. |
| Location: |
Montreal, Quebec |
| Industry Sector: |
Biotechnology - Therapeutics |
| Website: |
www.alethiabio.com |
| Contact: |
Mario Filion (mariof@alethiabio.com)
1 514 858 7666
|
| Description: |
Alethia Biotherapeutics is engaged in the discovery and development of targeted therapeutics.
The Company has prioritized the development of monoclonal antibodies with improved disease specificity against targets derived from its target discovery platform. |
| Location: |
Cheshire, Connecticut |
| Industry Sector: |
Biotechnology - Therapeutics |
| Website: |
www.alxn.com |
| Contact: |
Jeremy P. Springhorn (clinicaltrials@alxn.com)
1 203 2722596
|
| Ownership: |
Public - Nasdaq: ALXN |
| Description: |
Alexion is dedicated to working to develop and deliver life-changing drug therapies for patients with serious and life-threatening medical conditions including cancer, autoimmune disorders and hematologic diseases. |
| Location: |
Vancouver, British Columbia |
| Industry Sector: |
Biotechnology - Therapeutics |
| Website: |
www.allontherapeutics.com |
| Contact: |
Jacqueline Tiong (jtiong@allontherapeutics.com)
1 604 7360634
|
| Ownership: |
Public - TSX: NPC |
| Description: |
Allon Therapeutics Inc. is a clinical-stage biotechnology company focused on developing the first drugs that impact the progression of neurodegenerative diseases. Allon’s drug davunetide has demonstrated human efficacy in amnestic mild cognitive impairment, a precursor to Alzheimer’s disease, and schizophrenia-related cognitive impairment. Allon has Phase II human efficacy programs pursuing large markets of unmet medical need: frontotemporal dementia, Alzheimer’s disease, and schizophrenia-related cognitive impairment. The Company is listed on the Toronto Stock Exchange under the trading symbol “NPC” (Neuro Protection Company™) and based in Vancouver. |
| Location: |
Laval, Quebec |
| Industry Sector: |
Biotechnology - Therapeutics |
| Website: |
www.allostera.com |
| Contact: |
Mark Kaufmann (mkaufmann@allostera.com)
1 450 781 0479
|
| Description: |
Allostera Pharma Inc. is a bio pharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allostera’s initial focus is in the field of inflammation and autoimmunity. |
| Location: |
Toronto, Ontario |
| Industry Sector: |
Biotechnology - Therapeutics |
| Website: |
www.ambitbio.com |
| Contact: |
(sales@ambitbio.com)
1 416 673 8157
|
| Description: |
Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small-molecule kinase inhibitors for the treatment of cancer.
With more than 500 distinct kinases identified and over 30 kinase inhibitors in clinical trials or FDA approved, this important class of proteins is a rich area for therapeutic drug development. |
| Location: |
Mississauga, Ontario |
| Industry Sector: |
Pharma |
| Website: |
www.amgen.ca |
| Contact: |
Sabrina Paiva (spaiva@amgen.com)
1 905 2853000
|
| Ownership: |
Subsidiary - Nasdaq: AMGN |
| Description: |
Amgen Canada applies science and innovation to help fight serious illness and dramatically improve people's lives. Amgen contributes to the development of new therapies or new uses for existing medicines in partnership with many of Canada's leading healthcare, academic, research, government, and patient organizations. |
| Location: |
Mississauga, Ontario |
| Industry Sector: |
Biotechnology / R&D Services |
| Website: |
www.amorfix.com/ |
| Contact: |
Vigen Nazarian (vigen.nazarian@amorfix.com)
1 416 8476898
|
| Ownership: |
Public - TSX: AMF |
| Description: |
Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing therapeutic products and diagnostic devices targeting brain-wasting diseases including ALS, Alzheimer’s Disease, Parkinson’s Disease and variant Creutzfeldt-Jakob Disease (vCJD). |
| Location: |
Montreal, Quebec |
| Industry Sector: |
Biotechnology - Therapeutics |
| Website: |
www.angiochem.com |
| Contact: |
Catherine Gagnon (cgagnon@angiochem.com)
1 514 7887800
|
| Description: |
AngioChem is a clinical-stage biotechnology company discovering and developing novel drugs that cross the blood-brain barrier to treat brain diseases. These new Engineered Peptide Compounds (EPiC) have the potential to address significant medical needs, many of which cannot be effectively addressed due to the fundamental physiological challenge the blood-brain barrier presents for therapeutic intervention. AngioChem is developing a deep and broad product pipeline, including small and large molecules, for the treatment of a wide range of brain and brain related diseases including brain cancers, psychiatric disorders, neurodegenerative, metabolic diseases and others. |
| Location: |
Vancouver, British Columbia |
| Industry Sector: |
Medical Technology |
| Website: |
www.angiotech.com |
| Contact: |
K. Thomas Bailey (ir@angio.com)
1 604 221 7676
|
| Ownership: |
Public - TSX: ANP |
| Description: |
Angiotech Pharmaceuticals (NASDAQ:ANPI; TSX:ANP) is a world leader in the emerging field of drug-eluting medical devices and biomaterials. Angiotech is pioneering the science of adding drugs to medical devices and biomaterials to dramatically improve their performance and solve some of medicine's most vexing problems. |
| Location: |
Ottawa, Ontario |
| Industry Sector: |
Biotechnology - other |
| Website: |
www.apfuels.ca |
| Contact: |
Titch Dharamsi
1 613 297 7010
|
| Location: |
St. John's, Newfoundland |
| Industry Sector: |
Biotechnology - other |
| Website: |
www.aquabounty.com |
| Contact: |
David A. Frank (dfrank@aquabounty.com)
|
| Ownership: |
Subsidiary - LSE: ABTX |
| Description: |
Aqua Bounty Technologies is a biotechnology company focused on improving productivity in commercial aquaculture. |
| Location: |
Vancouver, British Columbia |
| Industry Sector: |
Biotechnology - Therapeutics |
| Website: |
www.aqxpharma.com |
| Contact: |
David J. Main (info@aqxpharma.com)
1 604 629 9223
|
| Description: |
Aquinox Pharmaceuticals Inc. is a privately-held, venture-backed, biopharmaceutical company developing novel and targeted small molecule therapeutics for the treatment of inflammatory disease and cancer. |
| Location: |
Ottawa, Ontario |
| Industry Sector: |
Medical Technology |
| Website: |
www.artenga.com |
| Contact: |
James Keenan (support@artenga.com)
1 612 322 8585
|
| Description: |
Artenga's goal is to develop medical devices to improve care for people with serious diseases. The current focus provides medical researchers with an effective, flexible means to develop treatments and diagnosis through the use of microbubbles. |
